Utilisation of data science to identify the system impact of COVID-19 on the cardiometabolic pathway, and identifying opportunities for transformation across Greater Manchester

A Collaborative Working Project between Health Innovation Manchester (HIM) and Boehringer Ingelheim Ltd (BIL) to identify the clinical and system impact of COVID-19 on the cardiometabolic pathway in Greater Manchester through the use of a machine learning algorithm. The outcome will include the identification of opportunities for transformation.

The project will aim to describe the backlog in care delivery impacting patients with cardiometabolic conditions within Greater Manchester (GM) as a result of COVID-19 pressures on the local health care system.  In addition, to identify opportunities to optimise clinical pathways in order to release capacity into the system as a whole. 

The collaboration will support the requirement to adapt the NHS service model in the Long-Term Plan¹ specifically in the areas out-of-hospital care, redesign, and reduction of pressure on hospital services with increased focus on population health, specifically in those patients with Type 2 Diabetes and cardiovascular disease.

This collaboration commenced in May 2022 and to be completed by mid-June 2023.

Boehringer Ingelheim Limited is delighted to collaborate with Health Innovation Manchester (and affiliated partners) to design and deliver this data science quality improvement programme.

Health Innovation Manchester is an Academic Health Science and Innovation System, at the forefront of transforming the health and wellbeing of the 2.8 million citizens in Greater Manchester.

Outcomes 

The collaboration was completed over 2 phases:

A feasibility Study of anonymised data was performed to provide a holistic view of the pathway which was then used to model predicted health system outcomes as defined by the project steering group.

References

1. The NHS Long Term Plan. Available at: NHS Long Term Plan 

NP-GB-104064    December 2023